Keystone Symposia

Whistler Conference Centre Floorplan

Registered Attendees

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2018

Here are the related meetings in 2021:
Antibodies and Vaccines as Drugs for COVID-19 (EK31)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibodies as Drugs: Translating Molecules into Treatments (C1)

Organizer(s) Paul W. H. I. Parren and Erica Ollmann Saphire
February 25—March 1, 2018
Whistler Conference Centre • Whistler, BC Canada
Discounted Abstract Deadline: Oct 24, 2017
Abstract Deadline: Nov 21, 2017
Scholarship Deadline: Oct 24, 2017
Discounted Registration Deadline: Dec 19, 2017

Sponsored by Bioverativ Therapeutics, Genentech, Inc., ImmunoGen, Inc., Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc. and Regeneron Pharmaceuticals, Inc.

Summary of Meeting:
Antibodies carry an enormous potential in prophylaxis and treatment of human disease. Antibody therapies may be divided into two distinct but highly related disciplines. First, antibodies can be elicited de novo using vaccines. Our understanding of what constitutes an effective antibody response at the molecular level and the science of eliciting such antibodies in vivo are progressing rapidly. Secondly, isolated antibodies represent powerful drugs when developed as biopharmaceuticals, as demonstrated by the ever-expanding list of approved molecules as well as by the large number of antibody products in development in a wide range of therapeutic areas. The antibody landscape is changing as the field has moved from empirical to knowledge-based, designer approaches for which understanding of mechanisms of action at the molecular level is critical. Translating such basic knowledge into novel products and applications requires scientists from many disciplines including structural and cellular immunology, biology, engineering, chemistry and medicine to interact closely. Consequently, the field of antibody-based vaccines and therapeutics has become an interface area where experts meet and work together. The 2018 Keystone Symposia antibodies conference aims to provide a platform for knowledge-sharing from the molecular to the systems level to navigate the newest developments and insights to prevent, treat and cure major human diseases.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time

The meeting will begin on Sunday, February 25 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 2 in order to fully experience the meeting.


Arrival and Registration

Grand Foyer
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Grand Foyer



Sea to Sky C
Welcome and Keynote Address

Sea to Sky B
* Paul W. H. I. Parren, Leiden University Medical Center, Netherlands

* Erica Ollmann Saphire, La Jolla Institute for Immunology, USA

* David I. Watkins, University of Miami, USA

Dennis R. Burton, The Scripps Research Institute, USA
Molecular Vaccine Design Guided by Human Anti-Viral Antibodies

Protective Antibody Responses

Sea to Sky B
* David I. Watkins, University of Miami, USA

George Georgiou, University of Texas at Austin, USA
The Human Serological and BCR Antibody Repertoires in Cancer, Autoimmunity or following Vaccination

Coffee Break

Erica Ollmann Saphire, La Jolla Institute for Immunology, USA
Systematic Analysis of Monoclonal Antibodies Against Ebola Virus GP Defines Features that Contribute to Protection

Antonio Lanzavecchia, Vir Biotechnology, Inc., USA
Lessons from the Analysis of the Immune Response to P. falciparum

Arthur S. Kim, Washington University School of Medicine, USA
Short Talk: Identification of Protective Antibody Epitopes on the Eastern Equine Encephalitis Virus Envelope Protein

Sarah Elliott, Wistar Institute, USA
Short Talk: DNA-Encoded Monoclonal Antibody (DMAb) for Acute Prophylaxis Against Influenza

Poster Setup

Poster Viewing

Grand Foyer
Workshop 1: Antibodies and Protection

Sea to Sky B
* Ann J. Hessell, Oregon Health & Science University, USA

Tongqing Zhou, NIAID, National Institutes of Health, USA
Structural Basis of Zika-Neutralizing Monoclonal Antibodies Elicited in Immunized Macaque Monkeys

Brett W. Jagger, Washington University, USA
Efficacy of Zika Virus Vaccines Against Zika Infection in Mice During Pregnancy

Laura A. Powell, Vanderbilt University, USA
Cross-Reactive and Potently Neutralizing Antibody Response in a Donor Naturally Infected with Ross River Virus

Natasha D. Durham, Tufts University, USA
Neutralizing Antibodies Remodel the Conformational Landscape of Ebola GP

Hideki Hasegawa, National Institute of Infectious Diseases, Japan
Enhancement of Anti-Viral Effects of an Intranasal Inactivated Influenza Vaccine-Derived Broadly Neutralizing Antibody by IgA Polymerization

Bryan Briney, The Scripps Research Institute, USA
Exceptionally Deep Antibody Repertoire Sequencing to Guide mAb Discovery and Development

Ron Diskin, Weizmann Institute of Science, Israel
Targeting TfR1-Tropic Arenaviruses at their Achilles Heel: Structure-Based Rational Design of Universal Immunotherapy

Matthijs M. Jore, Radboud University Medical Center, Netherlands
Engineered Antibodies Against Plasmodium Transmission from Man to Mosquito

Coffee Available

Grand Foyer
From Molecules to Vaccines

Sea to Sky B
* Erica Ollmann Saphire, La Jolla Institute for Immunology, USA

Nancy L. Haigwood, Oregon Health & Science University, USA
Antibody-Based HIV Therapeutics: "Hit Early, Hit Hard"

James E. Crowe, Jr., Vanderbilt University Medical Center, USA
Genetic and Structural Basis for Virus Neutralization by Human Antibodies

Robert F. Garry, Tulane University Health Sciences Center, USA
Antibody Treatment of Lassa Virus: From the Field to the Lab and Back

Ruoke Wang, Tsinghua University, China
Short Talk: Delineating Antibody Recognition Against Envelope Protein of Zika Virus during Natural Infection

Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky C
Poster Session 1

Grand Foyer



Sea to Sky C
Antibodies as Biopharmaceuticals

Sea to Sky B
Janine Schuurman, Genmab B.V., Netherlands
Therapeutic Antibody Panorama: Highways, Scenic Routes and Dead-Ends

Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Principles of Effective Antibody Therapeutics

Coffee Break

Marie H. Kosco-Vilbois, AC Immune, Switzerland
Creating Molecules that Succeed in the Clinic

Emma M. Lees, Bristol Myers Squibb, USA
JTX-2011: Mechanism of Action of an Agonist Antibody Targeting ICOS

* Ira Mellman, Genentech, Inc., USA
Antibodies in Cancer Immunotherapy

Cory Brooks, California State University, Fresno, USA
Short Talk: Glycosylation of MUC1 Influences the Binding of a Therapeutic Antibody by Altering the Conformational Equilibrium of the Antigen

Alexander W. Koch, Novartis Institutes for BioMedical Research, USA
Short Talk: Targeting Coagulation Factor XI (FXI) for Thrombosis Prevention

On Own for Lunch

Poster Setup

Grand Foyer
Poster Viewing

Grand Foyer
Coffee Available

Grand Foyer
Antibody Fc-Mediated Mechanisms I

Sea to Sky B
* Pierre Bruhns, Institut Pasteur, France

Pamela J. Bjorkman, California Institute of Technology, USA
Structural Studies of Antibody and Receptor Binding to HIV-1 Env

Jan Terje Andersen, Oslo University Hospital, Norway
HERA: A Human Endothelial Cell-Based Recycling Assay for Screening of FcRn Targeted Molecules

Jeffrey S. Miller, University of Minnesota, USA
Strategies to Use Trispecific Killer Engagers to Make NK Cells Antigen Specific

Julie M. Fox, Washington University, USA
Short Talk: Antibody Therapy Reduces Chikungunya Virus Disease through an FcgR-Dependent Mechanism

James A. Ernst, Genentech, Inc., USA
Short Talk: Optimizing Antibodies for Targeting the Tau Protein for Alzheimer's Disease and Other Tauopathies

Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky C
Poster Session 2

Grand Foyer



Sea to Sky C
Antibody Fc-Mediated Mechanisms II

Sea to Sky B
* Marjolein van Egmond, VU University Medical Center, Netherlands

Paul W. H. I. Parren, Leiden University Medical Center, Netherlands
Complement Activation at the Molecular Level

Suzan Huberdina Maria Rooijakkers, University Medical Center Utrecht, Netherlands
EMBO Young Investigator Lecture: Antibody-Mediated Killing of Bacteria by Complement

Coffee Break

Galit Alter, MIT and Harvard University, USA
Correlate Guided Approaches to Develop Antibodies Against Ebola Virus Infection

Pierre Bruhns, Institut Pasteur, France
Analyses of Single Ab-Secreting Cells using Droplet Microfluidics

David P. Humphreys, UCB Pharma, UK
Short Talk: On Target Hexamerisation of IgG1 Driven by a Mutant form of IgM Tail-Piece C-Terminal Fusion

Dieke J. van Rees, Sanquin Research and Landsteiner Laboratory, Netherlands
Short Talk: Sodium Stibogluconate in Conjunction with CD47-SIRP Checkpoint Blockade Enables Rituximab-Mediated Killing of B Lymphoma Cells by Neutrophils

On Own for Lunch

Workshop 2: Therapeutic Antibodies
- Structural aspects of antibodies, novel insights - Novel therapeutic antibody formats - Novel antibody technologies - From target to therapy - Newly approved and upcoming antibody therapeutics

Sea to Sky B
* Ida Hiemstra, Genmab, Netherlands

* Devin Sok, International AIDS Vaccine Initiative, USA
Non-Human Primate Pharmacokinetics of HIV Broadly Neutralizing Antibodies Isolated from Cow Immunizations

Amarendra Pegu, NIAID, National Institutes of Health, USA
Trispecific Antibodies Mediate Highly Potent and Broad Neutralization of HIV and Confer Expanded Protection Against SHIV Infection in Macaques

Sanjay Ram, University of Massachusetts, USA
Potentiation of Efficacy of a Candidate Immunotherapeutic Anti-Neisseria Gonorrhoeae Antibody by Enhancing IgG Fc Hexamer Formation

Nina G. Caculitan, Genentech, Inc., USA
Discovery of the Determinants of Antibody-Drug Conjugate Efficacy and a Novel Resistance Mechanism to Anti-HER2 Therapeutics

Jordana Griffiths, University of Southampton, UK
Targeting OX40 in Cancer Immunotherapy

John Engelhardt, Bristol-Myers Squibb Company, USA
Next Generation Anti-CTLA-4 Antibodies

Ezio Bonvini, MacroGenics, Inc, USA
Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing

Michael Johnston, Queen's University Belfast, UK
Development of AMG 655 Conjugated Polymeric Nanoparticles Targeting Death Receptor 5 for the Treatment of Pancreatic Cancer

Coffee Available

Grand Foyer
Exploiting Effector Cell Responses

Sea to Sky B
* Pamela J. Bjorkman, California Institute of Technology, USA

Sergio A. Quezada, University College London, UK
Regulatory T Cells, Polymorphisms and Response to Checkpoint Blockade: From Mechanisms to Potential Biomarkers

Bertrand Routy, Centre hospitalier de l’Université de Montréal, Canada
The Gut Microbiota as a Novel Predictor of Immune Checkpoint Inhibitors Response?

Marjolein van Egmond, VU University Medical Center, Netherlands
Translating Antibody–Effector Cell Cross-Talk to Immunotherapy

Maria Mar Naranjo, Centre National de la Recherche Scientifique, France
Short Talk: Key Immunomodulatory Role of Neutrophils in the Induction of Protective Immunity by Antiviral Monoclonal Antibodies

Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky C



Sea to Sky C
Novel Ways to Deliver Antibody Therapy

Sea to Sky B
* Janine Schuurman, Genmab B.V., Netherlands

Ugur Sahin, BioNTech AG, Germany
Antibody and mRNA-Based Therapeutics

Mark Cobbold, AstraZeneca, USA
Retargeting T Cells for Tumor Therapy

Coffee Break

Markus Schmid, University of Zurich, Switzerland
Paracrine Delivery of Therapeutic Proteins

Johannes Lutz, Curevac AG, Germany
mRNA-Encoded Antibodies for Passive Immunization

Kalie Mix, Sanofi, USA
Short Talk: Cytosolic Delivery of Antibodies

Jeffrey J. Bunker, University of Chicago, USA
Short Talk: Natural Polyreactive IgA Antibodies Coat the Intestinal Microbiota

On Own for Lunch

Coffee Available

Grand Foyer
From Molecules to the Clinic

Sea to Sky B
* Paul W. H. I. Parren, Leiden University Medical Center, Netherlands

David E. Szymkowski, Szymkowski David, USA
Exploring Novel Mechanisms of Action and Clinical Outcomes of Therapeutic Antibodies Fc-Engineered to Optimally Engage Fc Gamma RIIb

John M. Lambert, , USA
Antibody-Drug Conjugates (ADCs): The Magic Bullet Revisited

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Sea to Sky B
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky C
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Sea to Sky C



*Session Chair †Invited, not yet responded.

We gratefully acknowledge support for this conference from:

Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

Bioverativ Therapeutics Genentech, Inc.
ImmunoGen, Inc. Merck & Co., Inc.
OncoMed Pharmaceuticals, Inc. Pfizer Inc.
Regeneron Pharmaceuticals, Inc.

We gratefully acknowledge the generous grant for this conference provided by:

National Institutes of Health

Grant No. 1 R13 AI136247-01

Funding for this conference was made possible (in part) by 1 R13 AI136247-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge additional support for this conference from:

Adipogen International Berkeley Lights, Inc.
The Antibody Society Zymeworks

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

EMBO Young Investigator Programme

Genmab A/S

ImmunoGen, Inc.

Xencor, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email:,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email:,
Phone:+1 970-262-1179